1,5-dipentyl-1H-[1,2,3]triazole | 65539-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,5-dipentyl-1H-[1,2,3]triazole
• 英文别名: 1,5-Dipentyltriazole
• CAS: 65539-05-1
• 化学式: C₁₂H₂₃N₃
• 分子量: 209.335
• InChiKey: BUAAXMLCZPBHKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES
  申请人：Aileron Therapeutics, Inc.

  公开号：US20130210745A1

  公开（公告）日：2013-08-15

  Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.

  本文提供了肽类模拟大环化合物以及利用这些大环化合物治疗疾病的方法。
• TRIAZOLE MACROCYCLE SYSTEMS
  申请人：Aileron Therapeutics, Inc.

  公开号：US20160031936A1

  公开（公告）日：2016-02-04

  The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.

  本发明提供了新型肽类模拟大环以及其制备和使用方法，还提供了氨基酸类似物和大环形成连接剂，以及在它们的生产中有用的试剂盒。
• Peptidomimetic macrocycles and uses thereof
  申请人：AILERON THERAPEUTICS, INC.

  公开号：US10253067B2

  公开（公告）日：2019-04-09

  Methods for treating liquid cancer, determined to lack a p53 deactivation mutation, in a subject are provided. Also provided are peptidomimetic macrocycles for use in treatment of a liquid cancer, determined to lack a p53 deactivation mutation, in a subject.

  提供了用于治疗被确定为缺乏 p53 失活突变的液态癌症的方法。还提供了用于治疗被确定为缺乏 p53 失活突变的液态癌的拟肽大环。
• Highly active polypeptides and methods of making and using the same
  申请人：Longevity Biotech, Inc.

  公开号：US10772934B2

  公开（公告）日：2020-09-15

  This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

  本发明涉及由天然多肽类似物组成的新型组合物，其中类似物包括一种α-氨基酸和至少一种β-氨基酸。给药组合物可用于治疗或预防由生化或生物途径功能障碍引起的多种疾病状态。本发明的组合物和方法特别适用于鉴定体内受体活性的新型治疗调节剂，与天然翻译的多肽相比，本发明的类似物具有更长的半衰期和相关的生物活性。
• COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP2032545A2

  公开（公告）日：2009-03-11